COVID-19: Epygen Biotech receives funding from govt for new affordable vaccine

With an anticipated price point of less than Rs 150 per dose, this will be the first time an Indian company will be able to adopt the highly productive C1-cell protein production platform.

Related Keywords

India ,Wuhan ,Hubei ,China ,Israel ,Debayan Ghosh ,European Union Zoonotic Anticipation ,Department Of Biotechnology ,Preparedness Initiative ,Department Of Biotechnology India ,Epygen Biotech ,Receptor Binding Domain ,Epygen Biotech Founder ,Affordable Vaccine ,Covid Vaccine ,Hasei And Phase Ii Clinical Trials ,